Alnylam Pharmaceuticals (ALNY) Change in Receivables (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Change in Receivables came in at $31.6 million in Q2 2026, down 76.92% YoY from $136.9 million in Q2 2025, and down 71.38% on a QoQ basis from $110.4 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Change in Receivables (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Change in Receivables data on file, last reported at $31.6 million in Q2 2026.
- Quarterly Change in Receivables fell 76.92% year-over-year to $31.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $357.6 million (up 48.43% YoY) and the FY2025 annual result came in at $360.0 million, up 315.9% from the prior year.
- Change in Receivables declined to $31.6 million in Q2 2026, from $110.4 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $399.9 million in Q3 2025 to a low of -$184.2 million in Q4 2025.
- A 5-year average of $40.1 million and a median of $19.5 million in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables plunged 470.68% — and 2025, when it jumped 1913.17%.
- Tracing ALNY's Change in Receivables over 5 years: stood at $53.3 million in 2022, then slumped by 107.26% to -$3.9 million in 2023, then jumped by 1638.07% to $59.5 million in 2024, then plunged by 409.62% to -$184.2 million in 2025, then soared by 117.15% to $31.6 million in 2026.
- The last three Change in Receivables figures came in at $31.6 million (Q2 2026), $110.4 million (Q1 2026), and -$184.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.60 Mn |
| Jun 30, 2026 | 31.60 Mn |
| Mar 31, 2026 | 110.42 Mn |
| Mar 31, 2026 | 110.42 Mn |
| Dec 31, 2025 | -184.25 Mn |
| Dec 31, 2025 | -184.25 Mn |
| Sep 30, 2025 | 399.86 Mn |
| Sep 30, 2025 | 399.86 Mn |
| Jun 30, 2025 | 136.91 Mn |
| Jun 30, 2025 | 136.91 Mn |
| Mar 31, 2025 | 7.43 Mn |
| Mar 31, 2025 | 7.43 Mn |
| Dec 31, 2024 | 59.51 Mn |
| Dec 31, 2024 | 59.51 Mn |
| Sep 30, 2024 | 37.09 Mn |
| Sep 30, 2024 | 37.09 Mn |
| Jun 30, 2024 | -9.64 Mn |
| Jun 30, 2024 | -9.64 Mn |
| Mar 31, 2024 | -410,000.00 |
| Mar 31, 2024 | -410,000.00 |